The UK government has reiterated its request that pharmaceutical companies prepare for a no-deal Brexit, and has given five specific recommendations for how they can prepare:
- Go to gov.uk for information relevant to your businesses
Answer seven simple questions about your business on euexit.campaign.gov.uk to receive the guidance that is relevant to your business. Sign up for email updates here
- Find out which tariffs your business may face
The government’s Technical Notice provides businesses and the public with further guidance on tariffs for goods in a no-deal scenario. A Technical Notice for businesses about government plans to ensure continuity for the UK’s existing trade agreements if there is no Brexit deal is also available.
- Prepare for new customs and VAT procedures at the border
Businesses will need to complete additional paperwork and register for an EORI number to move goods between the UK and EU. The specific actions needed to take on customs, including simplified procedures here and details on VAT changes here
- Ensure you follow regulations to sell medical products in the EEA and UK
Medical suppliers will need to establish their MAHs, applicants and QPPV in the EEA to sell any products there. Businesses will also need UK establishments by the end of 2020 to sell in the UK
- Continue Right to Work checks and support EEA and Swiss citizens
Ensure you continue to conduct Right to Work checks for new employees using an EEA or Swiss citizen’s passport or national identity card, support employees applying to the EU Settlement Scheme and inform those arriving after a ‘no deal’ exit about European Temporary Leave to Remain.
Chief Executive of the BioIndustry Association (BIA), Steve Bates, has acknowledged the difficulties Brexit is causing the life sciences sector:
“I know many of you are, at high cost, making contingency plans for all eventualities . . . I am equally well aware of how the Westminster drama provides an unhelpful backdrop to those seeking global investment into UK businesses.”
For more information, please read the full article here.